| Primary |
| Product Used For Unknown Indication |
30.8% |
| Drug Use For Unknown Indication |
26.9% |
| Cystic Fibrosis |
11.5% |
| Pancreatic Insufficiency |
11.5% |
| Pain |
7.7% |
| Pancreaticoduodenectomy |
7.7% |
| Neuropathy Peripheral |
3.8% |
|
| Death |
29.4% |
| Weight Decreased |
17.6% |
| Food Intolerance |
11.8% |
| Abnormal Loss Of Weight |
5.9% |
| Anxiety |
5.9% |
| Crohn's Disease |
5.9% |
| Faeces Discoloured |
5.9% |
| Hospitalisation |
5.9% |
| Neuropathy Peripheral |
5.9% |
| Weight Increased |
5.9% |
|
| Secondary |
| Pain |
22.2% |
| Pancreatic Insufficiency |
22.2% |
| Product Used For Unknown Indication |
22.2% |
| Cystic Fibrosis |
11.1% |
| Drug Use For Unknown Indication |
11.1% |
| Pancreatitis Chronic |
5.6% |
| Renal Transplant |
5.6% |
|
| Faeces Discoloured |
37.5% |
| Anxiety |
12.5% |
| Oedema Mouth |
12.5% |
| Pancreatic Carcinoma Metastatic |
12.5% |
| Pancreatitis |
12.5% |
| Weight Increased |
12.5% |
|
| Concomitant |
| Drug Use For Unknown Indication |
15.9% |
| Product Used For Unknown Indication |
14.1% |
| Pancreatic Carcinoma |
7.9% |
| Nuclear Magnetic Resonance Imaging |
7.4% |
| Pain |
7.0% |
| Diabetes Mellitus |
6.8% |
| Pancreatic Carcinoma Metastatic |
5.6% |
| Hypertension |
4.8% |
| Gastrooesophageal Reflux Disease |
3.5% |
| Pancreatitis |
3.5% |
| Neuroendocrine Tumour |
3.1% |
| Sleep Disorder |
3.1% |
| Depression |
2.9% |
| Anxiety |
2.3% |
| Crohn's Disease |
2.3% |
| Cystic Fibrosis |
2.1% |
| Nuclear Magnetic Resonance Imaging Brain |
2.1% |
| Neoplasm Malignant |
1.9% |
| Cardiac Disorder |
1.7% |
| Insomnia |
1.7% |
|
| Vomiting |
21.9% |
| Weight Decreased |
18.1% |
| Type 2 Diabetes Mellitus |
6.7% |
| Ileus |
4.8% |
| Myalgia |
4.8% |
| Skin Induration |
4.8% |
| Death |
3.8% |
| Diabetes Mellitus Insulin-dependent |
3.8% |
| Pancreatitis |
3.8% |
| Hypoaesthesia |
2.9% |
| Hypoglycaemia |
2.9% |
| Pyrexia |
2.9% |
| Sinusitis |
2.9% |
| Sudden Death |
2.9% |
| Wheezing |
2.9% |
| Wrong Technique In Drug Usage Process |
2.9% |
| Anxiety |
1.9% |
| Disease Progression |
1.9% |
| Drug Effect Decreased |
1.9% |
| Drug Ineffective |
1.9% |
|
